The Role of the Endocannabinoid System in Psychiatric Disorders and Symptoms: a Pharmacological fMRI study.
Recruiting
- Conditions
- psychiatric disorders (schizophrenia, addiction, OCD, ADHD, depression), fMRI, THC, cannabinoid system
- Registration Number
- NL-OMON20111
- Lead Sponsor
- Prof. Dr. N.F. Ramsey
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
1. Healthy control or Diagnosed with one psychiatric disorder, according to DSM-IV criteria, axis I:
A. Schizophrenia;
Exclusion Criteria
1. Clinical significant abnormalities, except for the predetermined psychiatric disorder;
2. For healthy controls, first degree relatives with a psychiatric disorder according to DSM IV;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main study parameter is the blood oxygen level dependent (BOLD) signal.
- Secondary Outcome Measures
Name Time Method Behavioral parameters (two sets of visual analogue scales), cerebral blood flow (measured with Arterial Spin Labeling), the concentration of plasma THC and its main metabolites, and the performance on neuropsychological tests will be measured.